# Aktis Oncology share price today (Aktis Oncology, Inc., AKTS)

> Aktis Oncology, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AKTS · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/akts

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $15.20
- Revenue (Jun 2026): $3.4 M (+111.4% on a year ago)
- Profit (Jun 2026), incl. one-off: −$24.1 M (one-off item, see below)
- ROE: −34%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Aktis Oncology share price today? Aktis Oncology, Inc.'s share price was $15.20 at the close on 4 November 2026. That is 27.4% below its average price over the last 200 trading days. Since its first close in our records, on 16 January 2026, it has traded between $15 and $32, and at that close it sat 1% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 8 weeks running. Over the last 10 months the share price moved −23% while the S&P 500 moved +6%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 11 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Aktis Oncology pay? Aktis Oncology, Inc. pays no dividend. In the last 6 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Aktis Oncology on? Aktis Oncology is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Aktis Oncology profitable? Aktis Oncology, Inc. posted a net loss of $24.1 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $63.7 M. That loss is 713.5% of the quarter's revenue. The same quarter a year earlier lost $15.0 M. Read this profit with care: at −$24.1 M it is bigger than the quarter's whole revenue of $3.4 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −854.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Aktis Oncology make, and is it growing? Aktis Oncology, Inc. reported $3.4 M of revenue in the Jun 2026 quarter, +111.4% on the same quarter a year earlier. That is the 3rd quarter in a row with growth on the year before. Over 1 years it has grown 336.9% a year on average. The last full year, FY25, came in at $6.5 M. Recent pace: the last four quarters grew +111.6% on average, against 336.9% a year over the longer run, so this year is growing slower than its own long-run rate. ## How much of every $100 of sales does Aktis Oncology keep? Aktis Oncology, Inc. has almost no sales yet: FY25 revenue was $6.5 M. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Aktis Oncology's profit turning into cash? Aktis Oncology, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $64.1 M of cash, against −$63.7 M of profit. After $9.6 M of spending on assets, free cash was −$73.7 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Aktis Oncology's cash go? Aktis Oncology, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $12.4 M on assets over the last 2 years. Averaged over those years that is 95.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $12.4 M over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Aktis Oncology's P/E ratio, and how does it compare with its own history? Aktis Oncology, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Aktis Oncology, Inc. at 130.1× its FY25 revenue of $6.5 M. The P/E comes back here once profit turns positive. ## Is the Aktis Oncology business getting better or worse? Aktis Oncology, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Aktis Oncology earn on its capital? Aktis Oncology, Inc. earned a ROE of −34% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −66%, a number that says nothing useful about the business. ## Does Aktis Oncology have too much debt? Aktis Oncology, Inc. has total debt of $11.2 M against shareholder equity of $485 M as of Jun 2026, so its debt is 0.02× its equity, which is very little. Year by year, that ratio went from 0.01 in FY22 to 0.06 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Aktis Oncology shareholding pattern? 15.1% of Aktis Oncology, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 8.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Aktis Oncology from balance-sheet trouble? For Aktis Oncology, Inc., the Z-score is 8.98. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 8.98 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Aktis Oncology rank in its industry? There is no score against its industry: Aktis Oncology, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Aktis Oncology compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Aktis Oncology in size? Aktis Oncology is the 118th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Prime Medicine, Inc., Theravance Biopharma, Inc. and Pharming Group N.V. Just below it: Ardelyx, Inc., Arbutus Biopharma Corporation and Ginkgo Bioworks Holdings, Inc. ### Biotechnology companies close in size

1. [Prime Medicine, Inc.](https://www.sectoralpha.in/us/stocks/prme) $884 million
2. [Theravance Biopharma, Inc.](https://www.sectoralpha.in/us/stocks/tbph) $884 million
3. [Pharming Group N.V.](https://www.sectoralpha.in/us/stocks/phar) $880 million
4. Aktis Oncology, Inc. $845 million
5. [Ardelyx, Inc.](https://www.sectoralpha.in/us/stocks/ardx) $827 million
6. [Arbutus Biopharma Corporation](https://www.sectoralpha.in/us/stocks/abus) $803 million
7. [Ginkgo Bioworks Holdings, Inc.](https://www.sectoralpha.in/us/stocks/dna) $785 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [SmartFinancial, Inc.](https://www.sectoralpha.in/us/stocks/smbk) $847 million · Banks - Regional
2. [Cryoport, Inc.](https://www.sectoralpha.in/us/stocks/cyrx) $846 million · Integrated Freight & Logistics
3. Aktis Oncology, Inc. $845 million
4. [Forum Energy Technologies, Inc.](https://www.sectoralpha.in/us/stocks/fet) $845 million · Oil & Gas Equipment & Services
5. [Controladora Vuela Compañía de Aviación, S.A.B. de C.V.](https://www.sectoralpha.in/us/stocks/vlrs) $845 million · Airlines

## What else do people ask about Aktis Oncology? ### What is Aktis Oncology's stock price today? Aktis Oncology, Inc.'s stock price is $15.20. The whole company is worth $845 M on the market. In the last 52 weeks it traded between $15 to $32; today it is 1% of the way up from the low, 27.4% below its 200-day average (as of 4 November 2026). ### What were Aktis Oncology's latest quarterly results? Aktis Oncology, Inc. reported revenue of $3.4 M and a net loss of $24.1 M for the Jun 2026 quarter. Earnings per share were −$0.44. The operating margin was −854.0%, 455.4 percentage points higher than a year earlier (as of 4 November 2026). ### What is Aktis Oncology's market cap? Aktis Oncology, Inc.'s market capitalisation is $845 M at a stock price of $15.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Aktis Oncology performing? Aktis Oncology, Inc.'s latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 8 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Aktis Oncology's stock price go up? This page does not forecast Aktis Oncology, Inc.'s stock price. What it shows instead: the stock price is $15.20. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the Aktis Oncology story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Aktis Oncology a stock worth studying right now? What the numbers show: Aktis Oncology, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.